Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.
Reinhard Dummer
Consultant or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; Genta; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche; Spirig Pharma AG; Transgene
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; Genta; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche; Spirig Pharma AG; Transgene
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche; Transgene
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Marta Nyakas
No relevant relationships to disclose
Grant A. McArthur
Consultant or Advisory Role - Millennium (U); Novartis (U); Pfizer (U); Roche/Genentech (U)
Research Funding - Millennium; Novartis; Pfizer
Ragini Reiney Kudchadkar
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Carlos Gomez-Roca
No relevant relationships to disclose
Ryan J. Sullivan
No relevant relationships to disclose
Keith Flaherty
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Carla Murer
No relevant relationships to disclose
Daniela Michel
Employment or Leadership Position - Novartis
Zhongwen Tang
Employment or Leadership Position - Novartis
Laure A. De Parseval
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jean-Pierre Delord
No relevant relationships to disclose